News & Views
Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited will speak at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe,…
Read more
Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3,…
Read more
Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the…
Read more
Telix is pleased to announce that it has entered into a conditional purchase agreement with Eckert & Ziegler Strahlen and Medizintechnik Aktiengesellschaft to acquire a licensed radiopharmaceutical production facility in Seneffe,…
Read more
Telix Pharmaceuticals Limited is pleased to announce the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in…
Read more
Telix is pleased to share the company had a pre-NDA meeting with the United States Food and Drug Administration (FDA) on the 24th of July to discuss the Company’s plan…
Read more
Telix Pharmaceuticals Limited is pleased to provide appendix 4D half-year report for the six months ended 30th June…
Read more
Telix Pharmaceuticals Ltd is pleased to announce Appendix 3B – Issue of shares under Share Purchase Plan…
Read more
Telix Pharmaceuticals Limited is pleased to announce that the first Australian patient has been added to the Phase III ZIRCON study. The first Australian patient was dosed with TLX250-CDx at…
Read more
Telix Pharmaceuticals Limited is pleased to advise that, at closing on Friday 16th August 2019, subscriptions under the Company’s Share Purchase Plan (“SPP”) totaled approximately $9.6…
Read more